RxDoctor Payments Data

Lisa Hammock, NP

Family · Thomaston, GANPI 1366968729

Payments from drug & device makers

$5,174in general payments, 2019–2025

Across 329 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$775
  • Novo Nordisk$737
  • AbbVie$689
  • Lilly USA, LLC$430
  • Amarin Pharma, Inc.$354
  • AstraZeneca$336
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,174 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$36,718
Medicare patients
218
Services billed
1,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$23,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$20,326
JardianceEmpagliflozin13$11,422
EliquisApixaban14$10,709
Doxycycline Hyclate87$654
Prednisone88$509
Albuterol Sulfate HfaAlbuterol Sulfate24$493
Levothyroxine Sodium62$400
Gabapentin21$367
Atorvastatin Calcium58$354
Cephalexin53$323
Methocarbamol31$290
Amoxicillin50$199
Losartan Potassium30$191
Alprazolam25$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$737$23,72917 claims
GSKTrelegy Ellipta$58$20,32619 claims
Boehringer IngelheimJardiance$302$11,42213 claims
PfizerEliquis$96$10,70914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Thomaston

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →